Status:
COMPLETED
Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life.
Lead Sponsor:
Bayer
Conditions:
Healthy
Eligibility:
FEMALE
18-35 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the effects on the quality of life and BMI of new contraceptives.
Detailed Description
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Eligibility Criteria
Inclusion
- Female requiring contraceptives.
- Aged 18 to 35 if a non-smoker, aged 18 to 30 if a smoker.
- Regular menstrual cycle (defined as duration of 28 +/- 5 days).
Exclusion
- No Contraindication for OC use
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2004
Estimated Enrollment :
221 Patients enrolled
Trial Details
Trial ID
NCT00367276
Start Date
December 1 2002
End Date
May 1 2004
Last Update
October 11 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.